|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 2 | Prevalence of the fragile-X syndrome in mentally retarded boys in a Swedish county显示文摘 | Gustavson KH Blomquist HK Holmgren G | 1986 | Am J Med Genet1986，23，12： | 2 |
| 3 | High-performance linear algebra algorithms using new generalized data structures for matrices显示文摘 | Gustavson F G | 2003 | Journal of Research and Development2003，47，1： | 1 |
| 4 | Environmental factors that control microbial perchlorate reduction 显示文摘 | Chaudhuri S K O' Conner S M Gustavson R L Achenbach L A Coates J D | 2002 | Applied and Environment Microbiology2002，68，9： | 1 |
| 5 | Mutation of nucleotide 1762 in the core promoter region during hepatitis B seroconversion and its relation to liver damage in HBeAg carriers显示文摘 | Gustavson C Mardbery K | 1998 | J Med Virol1998，55，2： | 1 |
| 6 | Selection and modeling of sustainable development indicators:A case study of the Fraser River Basin,British Columbia 显示文摘 | Gustavson R Lonergan C Ruitenbeek H J | 1999 | Ecological Economics1999，28，： | 1 |
| 7 | Precision Rotation Measurements with an Atom Interferometer Gyroscope显示文摘 | Bouyer P Kasevich M A | 1997 | Physical Review Letters1997，78，11： | 1 |
| 8 | Mutation of nu-cleotide 1762 in the core promoter region during hepatitis B seroconversion and its relation to liver damage in HBeAg car-riers显示文摘 | Gustavson C Mardbery K | 1998 | J Med Virol1998，55，2： | 1 |
| 9 | Rotation sensing with a dual atom-interferometer Sagnac gyroscope显示文摘 | Gustavson T L Landragin A Kasevich M A | 2000 | Classical and Quantum Gravity2000，17，12： | 1 |
| 10 | Selection and modeling of sustainable development indicators: A case study of the Fraser River Basin, British Columbia显示文摘 | Gustavson R Lonergan C Ruitenbeek H J | 1999 | Ecological Economics1999，28，： | 1 |
| 11 | Pharmaxokinetics and tolerability of extended-release clarithromycin显示文摘 | Guay DR Gustavson LE Devcich KJ | 2001 | Clin Ther2001，23，4： | 1 |
| 12 | Rotation sensing with a dual atom interferometer sagnac gyroscope显示文摘 | Gustavson T L Landragin A Kasevich M A | | 0，，： | 1 |
| 13 | Pharmacokinetics and tolerability of extended-release clarithromycin 显示文摘 | Guay DR Gustavson LE Devcich KJ | 2001 | Clin Ther2001，23，4： | 1 |
| 14 | Environmental Properties of Vitrified Fly Ash from Hazardous and Municipal Waste Incineration显示文摘 | GUSTAVSON B | 2000 | Waste Management2000，20，： | 1 |
| 15 | The PEA3 subfamily of Ets transcription factors synergizes with β-cateninLEF-1 to activate matrilysin transcription in intestinal tumors显示文摘 | Crawford HC Fingleton B Gustavson MD | 2001 | Mol Cell Biol2001，21，4： | 1 |
| 16 | Anti-aliased Euclidean distance transform显示文摘 | GUSTAVSON S STRAND R | | 0，，： | 1 |
| 17 | The PEAS subfamily of Ets transcription factors synergizes with R-Catenin-LEF-1 to activate matrilysin transcription in intestinal tumors显示文摘 | Crawford HC Fingleton B Gustavson MD | 2001 | Mol Cell Biol2001，21，4： | 1 |
| 18 | Population analysis of the pharmacokinetics of Tiagabine in patients with epilepsy显示文摘 | Gustavson LE El-Shourbagy T Locke C Granneman GR Sommerville KW | 1998 | Epilepsia1998，39，： | 1 |
| 19 | The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors显示文摘 | Crawford HC Fingleton B Gustavson MD | 2001 | Mol Cell Biol2001，21，4： | 1 |
| 20 | Pharmacokinetics and tolerability of extended-release clarithromycin显示文摘 | Guay D R Gustavson L E Devcich K J | 2001 | Clin Ther2001，23，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员